Novel agents to inhibit microbial virulence and pathogenicity

Bibliography

• Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64(Suppl 1):i29-36
   PubMed Web of Science ®Google Scholar
• Terzulli LS, Croft CA, D'Antoni VA. Update on the antibacterial resistance crisis. Med Sci Monit 2007;13:103-18
   Google Scholar
• Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 2005;36:697-705
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40
   PubMed Web of Science ®Google Scholar
• Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther 2008;6:39-49
   PubMed Web of Science ®Google Scholar
• Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008;6:17-27
   PubMed Web of Science ®Google Scholar
• Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 2008;12:1-9
   Google Scholar
• Alekshun NM, Levy SB. Targeting virulence to prevent infection: to kill or not to kill? Drug Discov Today 2004;1:483-9
   Google Scholar
• Marra A. Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery. Drugs RD 2006;7:1-16
   Google Scholar
• Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3:541-8
   PubMed Web of Science ®Google Scholar
• Sasakawa C, Hacker J. Host-microbe interaction: bacteria. Curr Opin Microbiol 2006;6:1-4
   Google Scholar
• Benton BM, Zhang JP, Bond S, Large-scale identification of genes required for full virulence of Staphylococcus aureus. J Bacteriol 2004;186:8478-89
   PubMed Web of Science ®Google Scholar
• Freiberg C, Brotz-Oesterhelt H. Functional genomics in antibacterial drug discovery. Drug Discov Today 2005;10:927-35
   PubMed Web of Science ®Google Scholar
• Burrack SL, Higgins ED. Genomic approaches to understanding bacterial virulence. Curr Opin Microbiol 2007;10:4-9
   Google Scholar
• Wu HJ, Wang AH, Jennings MP. Discovery of virulence factors of pathogenic bacteria. Curr Opin Chem Biol 2008;12:93-101
   PubMed Web of Science ®Google Scholar
• Kong KF, Vuong C, Otto M. Staphylococcus quorum sensing in biofilm formation and infection. Int J Med Microbiol 2006;296:133-9
   PubMed Web of Science ®Google Scholar
• Atkinson S, Williams P. Quorum sensing and social networking in the microbial world. J R Soc Interface 2009;6:959-78
   PubMed Web of Science ®Google Scholar
• Bronner S, Monteil H, Prevost G. Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. FEMS 2004;28:183-200
   Google Scholar
• Pan J, Ren D. Quorum sensing inhibitors: a patent overview. Expert Opin Ther Patents 2009;19:1581-601
   PubMed Web of Science ®Google Scholar
• Ni N, Li M, Wang J, Wang B. Inhibitors and antagonists of bacterial quorum sensing. Med Res Rev 2009;291:65-124
   Google Scholar
• University New York. B. anthracis prevention and treatment: mutant B. anthracis lacking luxS activity and furanone inhibition of growth, AI-2 QS and toxin production. US299153; 2008
   Google Scholar
• Wu H, Song Z, Hentzer M, Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother 2004;53:1054-61
   PubMed Web of Science ®Google Scholar
• Christensen DL, Moser C, Jensen P, Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. Microbiology 2007;153:2312-20
   PubMedGoogle Scholar
• Ventre I, Goodman LA, Vallet-Gely I, Multiple sensors control reciprocal expression of Pseudomonas aeruginosa regulatory RNA and virulence genes. Proc Natl Acad Sci USA 2006;103:171-6
   PubMed Web of Science ®Google Scholar
• Williams P, Camara M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol 2009;12:182-91
   PubMed Web of Science ®Google Scholar
• University New York. Combinatorial libraries of autoinducer analogs: autoinducer agonists and antagonist and methods of use thereof. US027115; 2008
   Google Scholar
• Yang L, Rybtke MT, Jakobsen TH, Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitors. Antimicrob Agents Chemother 2009;53:2432-43
   PubMed Web of Science ®Google Scholar
• Quonova GmbH. Inhibitors of biofilm formation of Gram-positive and Gram-negative bacteria. US192192; 2009
   Google Scholar
• Wisconsin Alumni Res Found. Modulation of bacterial quorum sensing with synthetic ligands. WO084056; 2006
   Google Scholar
• University Georgia State. Composition for regulating or modulating quorum sensing in bacterial, methods of using the compounds and methods of regulating or modulating quorum sensing in bacteria. WO029317; 2009
   Google Scholar
• Ni N, Choudhary G, Li M, Wang B. Pyrogallol and its analogs can antagonize bacterial quorum sensing in Vibrio harveyi. Bioorg Med Chem Lett 2008;18:1567-72
   PubMed Web of Science ®Google Scholar
• University Princeton. Identification of bacterial autoinducer and use in treating bacterial pathogenicity. WO088402; 2009
   Google Scholar
• Swem LR, Swem DL, O'Loughlin CT, A quorum-sensing antagonist targets both membrane-bound and cytoplasmic receptors and controls bacterial pathogenicity. Mol Cell 2009;35:143-53
   PubMed Web of Science ®Google Scholar
• Reading NC, Rasko DA, Torres AG, Sperandio V. The two-component system QseEF and the membrane protein QseG link adrenergic and stress sensing to bacterial pathogenesis. Proc Natl Acad Sci USA 2009;106:5889-94
   PubMed Web of Science ®Google Scholar
• Rasko DA, Moreira CG, Li R, Targeting QseC signaling and virulence for antibiotic development. Science 2008;321:1078-80
   PubMed Web of Science ®Google Scholar
• Lesic B, Lepine F, Deziel E, Inhibitors of pathogen intercellular signals as selective anti-infective compounds. PLoS Pathog 2007;3:1229-39
   PubMed Web of Science ®Google Scholar
• Rasmussen BT, Skindersoe EM, Jarnsholt BT, Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology 2005;151:1325-40
   PubMed Web of Science ®Google Scholar
• Adonizio A, Kon K-F, Mathee K. Inhibition of quorum sensing-controlled virulence factor production in Pseudomonas aeruginosa by South Florida plant extracts. Antimicrob Agents Chemother 2008;52:198-203
   PubMed Web of Science ®Google Scholar
• Florida University. Use of as inhibitors of bacterial quorum sensing. WO114810; 2009
   Google Scholar
• Raina S, De Vizio D, Odell M, Microbial quorum sensing: a tool or a target for antimicrobial therapy? Biotechnol Appl Biochem 2009;54:65-84
   PubMed Web of Science ®Google Scholar
• Bronner S, Monteil H, Prevost G. Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. FEMS 2004;28:183-200
   Google Scholar
• Camargo IL, Gilmore MS. Staphylococcus aureus: probing for host weakness? J Bacteriol 2008;190:2253-6
   Google Scholar
• George AE, Novick PR, Muir WT. Cyclic peptide inhibitors of Staphylococcal virulence prepared by Fmoc-based thiolactone peptide synthesis. J Am Chem Soc 2008;130:4914-24
   PubMed Web of Science ®Google Scholar
• Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections. US009567; 2007
   Google Scholar
• Balaban N, Cirioni O, Giacometti A, Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 2007;51:2226-9
   PubMed Web of Science ®Google Scholar
• Janda K, Kaufmann G. Antibody-mediated disruption of quorum sensing in bacteria. WO055054; 2009
   Google Scholar
• Park J, Jagasia R, Kaufmann FG, Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 2007;14:1119-27
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Eliopoulos MG, Fowler G, Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005;49:2687-92
   PubMedGoogle Scholar
• Yarwood MJ, Paquette MK, Tikh I, Generation of virulence factor variants in Staphylococcus aureus biofilms. J Bacteriol 2007;189:7961-7
   PubMed Web of Science ®Google Scholar
• Aberg V, Sellstedt M, Hedenstrom M, Design, synthetis and evaluation of peptidomimetics based on substituted bicyclic 2-pyridones-targeting virulence of uropathogenic E. coli. Bioorg Med Chem Lett 2006;14:7563-81
   Google Scholar
• University Washington. Amino methylated 2-pyridinones. US311644; 2008
   Google Scholar
• Pinkner SJ, Remaut H, Buelens F, Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA 2006;103:17897-902
   PubMed Web of Science ®Google Scholar
• Shakhnovich EA, Hung DT, Pierson E, Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci USA 2007;104:2372-7
   PubMed Web of Science ®Google Scholar
• Brutinel ED, Yahr TL. Control of gene expression by type III secretory activity. Curr Opin Microbiol 2008;11:128-33
   Google Scholar
• Galan JE, Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion machines. Nature 2006;444:567-73
   PubMed Web of Science ®Google Scholar
• Baron C. Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 2010;13:100-5
   PubMed Web of Science ®Google Scholar
• Pan N, Brady M, Leong J, Goguen J. Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother 2009;53:385-92
   PubMed Web of Science ®Google Scholar
• Kauppi AM, Andersson CD, Norberg H, Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. Bioorg Med Chem 2007;15:6994-7011
   PubMed Web of Science ®Google Scholar
• Innate Pharmaceuticals AB. Method and means for preventing and inhibiting type III secretion in infections caused by Gram-negative bacteria. EP1543148; 2005
   Google Scholar
• Dahlgren MK, Kauppi AM, Olsson IM, Design, synthesis, and multivariate quantitative structure–activity relationship of salicylanilides, potent inhibitors of type III secretion in Yersinia. J Med Chem 2007;50:6177-88
   PubMed Web of Science ®Google Scholar
• Hudson DL, Layton AN, Field TR, Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob Agents Chemother 2007;51:2631-5
   PubMed Web of Science ®Google Scholar
• Negrea A, Bjur E, Ygberg SE, Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 2007;8:2867-76
   Google Scholar
• Bailey L, Gylfe A, Sundin C, Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett 2007;581:587-95
   PubMed Web of Science ®Google Scholar
• Wolf K, Betts J, Chellas-Gery B, Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol 2006;61:1543-55
   PubMed Web of Science ®Google Scholar
• Innate Pharmaceuticals AB. N-substituted 7-quinolylmethyl amine. WO115118; 2008
   Google Scholar
• University Massachusetts, Harvard College. Type III secretion inhibitors analogues and uses thereof. WO145829; 2009
   Google Scholar
• Pan NJ, Brady MJ, Leong JM, Goguen JD. Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother 2009;53:385-92
   PubMed Web of Science ®Google Scholar
• University Washington. 5-Substituted-2-imino-thiozolidinone compounds and their use as inhibitors of bacterial infection. WO137133; 2009
   Google Scholar
• Kline T, Barry KC, Jackson SR, Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system. Bioorg Med Chem Lett 2009;19:1340-3
   PubMed Web of Science ®Google Scholar
• Felise HB, Nguyen HV, Pfuetzner RA, An inhibitor of Gram-negative bacterial virulence protein secretion. Cell Host Microbe 2008;4:325-36
   PubMed Web of Science ®Google Scholar
• Bowser TE, Bartlett VJ, Grier MC, Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors. Bioorg Med Chem Lett 2007;17:5652-5
   PubMed Web of Science ®Google Scholar
• Paratek Pharma, Inc. Transcription factor modulating compounds and methods of use thereof. WO005551; 2009
   Google Scholar
• Kim OK, Garrity-Ryan LK, Bartlett VJ, N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. J Med Chem 2009;52:5626-34
   PubMed Web of Science ®Google Scholar
• Marraffini LA, DeDent AC, Schneewind O. Sortases and the art of anchoring proteins to the envelopes of Gram-positive bacteria. Microbiol Mol Biol Rev 2006;1:192-221
   Google Scholar
• Maresso WA, Schneewind O. Sortase as a target of anti-infective therapy. Pharmacol Rev 2008;60:128-41
   PubMed Web of Science ®Google Scholar
• Kruger RG, Barkallah S, Frankel BA, McCafferty DG. Inhibition of the Staphylococcus aureus sortase transpeptidase SrtA by phosphinic peptidomimetics. Bioorg Med Chem Lett 2004;12:3723-9
   Google Scholar
• Ki-Bong O, Soo-Hwan K, Jaekwang L, Discovery of diarylacrylonitriles as a novel series of small molecule Sortase A inhibitors. J Med Chem 2004;47:2418-21
   Google Scholar
• Kang SS, Kim JG, Lee TH, Ki-Bong O. Flavonols inhibit sortases and sortase-mediated Staphylococcus aureus clumping to fibrinogen. Biol Pharm Bull 2006;29:1751-6
   PubMed Web of Science ®Google Scholar
• Maresso AW, Wu R, Kern JW, Activation of inhibitors by sortase triggers irreversible modification of the active site. J Biol Chem 2007;282:23129-39
   PubMed Web of Science ®Google Scholar
• Chennaa BC, Shinkrea BA, Kinga JR, Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A. Bioorg Med Chem Lett 2008;18:380-5
   Google Scholar
• UAB Research Foundation. Novel inhibitors of bacterial sortase enzymes and methods of using the same. WO023160; 2009
   Google Scholar
• Jang KH, Chung SC, Shin J, Aaptamines as sortase A inhibitors from the tropical sponge Aaptos aaptos. Bioorg Med Chem Lett 2007;17:5366-9
   PubMed Web of Science ®Google Scholar
• Ferreras JA, Ryu JS, Di Lello F, Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat Chem Biol 2005;1:29-32
   PubMed Web of Science ®Google Scholar
• Sloan Kettering Inst Cancer, Cornell Res Foundation. Antimicrobial agents and uses thereof. WO113615; 2006
   Google Scholar
• Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007;71:413-51
   PubMed Web of Science ®Google Scholar
• Miethke M, Bisseret P, Beckering CL, Inhibition of aryl acid adenylation domains involved in bacterial siderophore synthesis. FEBS J 2006;273:409-19
   PubMed Web of Science ®Google Scholar
• Neres J, Labello NP, Somu RV, Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure–activity relationships of the nucleobase domain of 5′-O-[-N-(salicyl)sulfamoyl]adenosine. J Med Chem 2008;51:5349-70
   PubMed Web of Science ®Google Scholar
• Neres J, Wilson DJ, Celia L, Aryl acid adenylating enzymes involved in siderophore biosynthesis: fluorescence polarization assay, ligand specificity, and discovery of non-nucleoside inhibitors via high-throughput screening. Biochemistry 2008;47:11735-49
   Google Scholar
• Skaar EP, Humayun M, Bae T, Iron-source preference of Staphylococcus aureus infections. Science 2004;305:1626-8
   PubMed Web of Science ®Google Scholar
• Torres VJ, Stauff DL, Pishchany G, A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence. Cell Host Microbe 2007;1:109-19
   PubMed Web of Science ®Google Scholar
• Skaar E. Antimicrobial compounds and methods of use therof. US004324; 2010
   Google Scholar
• Brown KL, Hancock RE. Cationic host defence peptides. Curr Opin Immunol 2006;18:24-30
   PubMed Web of Science ®Google Scholar
• Liu CI, Liu YG, Song Y, A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008;319:1391-4
   PubMed Web of Science ®Google Scholar
• University California. Antimicrobial therapy for bacterial infections. WO133712; 2007
   Google Scholar
• Bryk R, Gold B, Venugopal A, Selective killing of nonreplicating mycobacteria. Cell Host Microbe 2008;3:137-45
   PubMed Web of Science ®Google Scholar
• Decode Chemistry, Inc. Cyclic carboxylic acid rhodamine derivatives for the treatment and prevention of tuberculosis. WO005651; 2008
   Google Scholar
• Zhou B, He Y, Zhang X, Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc Natl Acad Sci USA 2010;107:4573-8
   PubMed Web of Science ®Google Scholar
• Rosenfeld Y, Shai Y. Lipopolysaccharide (endotoxin)-host defence antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochimi et Biophys Acta 2006;1757:1513-22
   Google Scholar
• Kline T, Trent MS, Stead CM, Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. Bioorg Med Chem Lett 2008;18:1507-10
   Google Scholar
• Harper M, Cox AD, St Michael F, A heptosyltransferase mutant of Pasteurella multocida produces a truncated lipopolysaccharide structure and is attenuated in virulence. Infect Immun 2004;72:3436-43
   Google Scholar
• Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002;71:635-700
   PubMed Web of Science ®Google Scholar
• Kim CH. A Salmonella typhimurium rfaE mutant recovers invasiveness for human epithelial cells when complemented by wild type rfaE (controlling biosynthesis of ADP-L-glycero-beta-D-manno-heptose-containing lipopoly-saccharide). Mol Cells 2003;15:226-32
   Google Scholar
• De Leon GP, Elowe NH, Koteva KP, An in vitro screen of bacterial lipopolysaccharide biosynthetic enzymes identifies an inhibitor of ADP-heptose biosynthesis. Chem Biol 2006;13:437-41
   Google Scholar
• Mutabilis SA. New chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors. WO038136; 2008
   Google Scholar
• Desroy N, Moreau F, Briet S, Towards Gram-negative antivirulence drugs: new inhibitors of HldE kinase. Biorg Med Chem Lett 2009;17:1276-89
   Google Scholar
• Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med 2003;254:197-215
   PubMed Web of Science ®Google Scholar
• Weidenmaier C, Peschel A. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat Rev Microbiol 2008;6:276-87
   PubMed Web of Science ®Google Scholar
• Peschel L, Otto M, Jack WR, Inactivation of dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 1999;274:8405-10
   PubMed Web of Science ®Google Scholar
• Kovacs M, Halfmann A, Fedtke I, A functional dlt operon, encoding proteins required for incorporation of D-alanine in teichoic acids in Gram-positive bacteria, confers resistance to cationic antimicrobial peptides in Streptococcus pneumoniae. J Bacteriol 2006;188:5797-805
   PubMed Web of Science ®Google Scholar
• Neuhaus FC, Baddiley J. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in Gram-positive bacteria. Microbiol Mol Biol Rev 2003;67:686-723
   PubMed Web of Science ®Google Scholar
• Fabretti F, Theilacker C, Baldassarri L, Alanine esters of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides. Infect Immun 2006;74:4164-71
   Google Scholar
• May JJ, Finking R, Wiegeshoff F, Inhibition of the D-alanine:D-alanyl carrier protein ligase from Bacillus subtilis increases the bacterium's susceptibility to antibiotics that target the cell wall. FEBS J 2005;272:2993-3003
   PubMed Web of Science ®Google Scholar
• Biosynexus, Inc. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria. WO059260; 2003
   Google Scholar
• Weisman LE, Thackray HM, Garcia-Prats JA, Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009;53:2879-86
   PubMed Web of Science ®Google Scholar
• Mutabilis SA. New imidazolo-heteroaryl derivatives and biological applications thereof. WO117225; 2008
   Google Scholar
• Escaich S, Moreau F, Malacain E, Discovery of new Gram positive antivirulence drugs2: the first antivirulence molecule active in vivo [abstract F2-958]. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September 2007; Chicago, IL, USA
   Google Scholar